| Fabiola Hilaire, | |
|
619 Crystal Ct, Villa Rica, GA 30180-5151 | |
| (631) 901-9084 | |
| Not Available |
| Full Name | Fabiola Hilaire |
|---|---|
| Gender | Female |
| Speciality | Licensed Vocational Nurse |
| Location | 619 Crystal Ct, Villa Rica, Georgia |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1770252652 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 164X00000X | Licensed Vocational Nurse | 301086 (New York) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Fabiola Hilaire, 619 Crystal Ct, Villa Rica, GA 30180-5151 Ph: (631) 901-9084 | Fabiola Hilaire, 619 Crystal Ct, Villa Rica, GA 30180-5151 Ph: (631) 901-9084 |
News Archive
Sex-specific cardiovascular drug dosages are needed to reduce adverse reactions in women, according to a position paper from the European Society of Cardiology published today in the June issue of European Heart Journal - Cardiovascular Pharmacotherapy.
Invision Sally Jobe is among the first diagnostic imaging networks in the nation to offer a new breast ultrasound technology for the early detection of cancer. Screening Breast Ultrasound is a highly effective technology developed to complement mammography in women with radiologically dense breasts and other risk factors.
An analysis of quality of cardiac care following the public release of data on measures of care at hospitals in Ontario, Canada, did not result in significant systemwide improvement in hospitals' performance on most quality of care indicators, according to a study to be published in the December 2 issue of JAMA. The study is being released early online because of its presentation at an American Heart Association scientific conference.
The Food and Drug Administration (FDA) has requested that Novartis Pharmaceuticals Corporation of East Hanover, New Jersey, voluntarily discontinue marketing of Zelnorm (tegaserod) based on the recently identified finding of an increased risk of serious cardiovascular adverse events (heart problems) associated with use of the drug. Novartis has agreed to voluntarily suspend marketing of the drug in the United States.
Researchers at the Graduate Entry Medical School, University of Limerick (GEMS) have been awarded €175,000 funding to develop a portable automated device that can be used in any clinical or community setting to allow early diagnosis and treatment of delirium.
› Verified 4 days ago